Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Research article

Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity

Authors: Tahnee Sente, An M. Van Berendoncks, An I. Jonckheere, Richard J. Rodenburg, Patrick Lauwers, Viviane Van Hoof, An Wouters, Filip Lardon, Vicky Y. Hoymans, Christiaan J. Vrints

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Background

Peripheral skeletal muscle wasting is a common finding with adverse effects in chronic heart failure (HF). Whereas its clinical relevance is beyond doubt, the underlying pathophysiological mechanisms are not yet fully elucidated. We aimed to introduce and characterize the primary culture of skeletal muscle cells from individual HF patients as a supportive model to study this muscle loss.

Methods and results

Primary myoblast and myotubes cultures were successfully propagated from the m. vastus lateralis of 6 HF patients with reduced ejection fraction (HFrEF; LVEF <45 %) and 6 age and gender-matched healthy donors. HFrEF cultures were not different from healthy donors in terms of morphology, such as myoblast size, shape and actin microfilament. Differentiation and fusion indexes were identical between groups. Myoblast proliferation in logarithmic growth phase, however, was attenuated in the HFrEF group (p = 0.032). In addition, HFrEF myoblasts are characterized by a reduced TNFR2 expression and IL-6 secretion (p = 0.017 and p = 0.016; respectively).

Conclusion

Biopsy derived primary skeletal muscle myoblasts of HFrEF patients produce similar morphological and myogenic differentiation responses as myoblasts of healthy donors, though demonstrate loss of anti-inflammatory and proliferative activity.
Appendix
Available only for authorised users
Literature
1.
Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol. 2002;85(1):33–49.CrossRefPubMed
2.
Wust RC, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(3):289–300.PubMedPubMedCentral
3.
Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. Am J Geriatr Cardiol. 2015;12(3):294–304.
4.
Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265–79.CrossRefPubMed
5.
von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007;73(2):298–309.CrossRef
6.
Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W, Anker SD, von Haehling S. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512–9.CrossRefPubMed
7.
Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85(4):1364–73.CrossRefPubMed
8.
Lauren Cornall DH, Michael Mathai and Andrew McAinch.: Generation and Use of Cultured Human Primary Myotubes. In: Muscle Biopsy. edn.; 2012: 35-64.
9.
Danoviz ME, Yablonka-Reuveni Z. Skeletal muscle satellite cells: background and methods for isolation and analysis in a primary culture system. Methods Mol Biol. 2012;798:21–52.CrossRefPubMedPubMedCentral
10.
Yablonka-Reuveni Z. Isolation and culture of myogenic stem cells. In: Lanza RBH, Melton D, Moore M, Thomas ED, Verfaillie C, Weissman IL, editors. Handbook of Stem Cells. San Diego: Elsevier, Academic Press; 2004. p. 571–80.CrossRef
11.
Barro M, Carnac G, Flavier S, Mercier J, Vassetzky Y, Laoudj-Chenivesse D. Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. J Cell Mol Med. 2010;14(1-2):275–89.CrossRefPubMedPubMedCentral
12.
Berggren JR, Tanner CJ, Houmard JA. Primary cell cultures in the study of human muscle metabolism. Exerc Sport Sci Rev. 2007;35(2):56–61.CrossRefPubMed
13.
McAinch AJ, Steinberg GR, Mollica J, O’Brien PE, Dixon JB, Kemp BE, Cameron-Smith D. Leptin stimulation of COXIV is impaired in obese skeletal muscle myotubes. Obesity Res Clin Pract. 2007;1(1):1–78.CrossRef
14.
Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975;35(7):609–16.CrossRefPubMed
15.
Gaster M, Beck-Nielsen H, Schroder HD. Proliferation conditions for human satellite cells. The fractional content of satellite cells. Acta Pathol Microbiol Immunol Scand. 2001;109(11):726–34.CrossRef
16.
Filigheddu N, Gnocchi VF, Coscia M, Cappelli M, Porporato PE, Taulli R, Traini S, Baldanzi G, Chianale F, Cutrupi S, et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell. 2007;18(3):986–94.CrossRefPubMedPubMedCentral
17.
Yip DJ, Picketts DJ. Increasing D4Z4 repeat copy number compromises C2C12 myoblast differentiation. FEBS Lett. 2003;537(1-3):133–8.CrossRefPubMed
18.
Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O, Pauwels P. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012;7(10):e46536.CrossRefPubMedPubMedCentral
19.
Berendse M, Grounds MD, Lloyd CM. Myoblast structure affects subsequent skeletal myotube morphology and sarcomere assembly. Exp Cell Res. 2003;291(2):435–50.CrossRefPubMed
20.
Pomies P, Rodriguez J, Blaquiere M, Sedraoui S, Gouzi F, Carnac G, Laoudj-Chenivesse D, Mercier J, Prefaut C, Hayot M. Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients. J Cell Mol Med. 2015;19(1):175–86.CrossRefPubMedPubMedCentral
21.
Thingholm TE, Bak S, Beck-Nielsen H, Jensen ON, Gaster M: Characterization of human myotubes from type 2 diabetic and nondiabetic subjects using complementary quantitative mass spectrometric methods. Mol. Cell. Proteomics 2011, 10(9):M110 006650.
22.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93(4):704–11.CrossRefPubMed
23.
Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, Kassiri Z, Oudit GY, Alberta HI. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One. 2014;9(6):e99495.CrossRefPubMedPubMedCentral
24.
Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115(1):1–20.CrossRefPubMedPubMedCentral
25.
Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, Ooi CJ, Xavier RJ, Terhorst C, Podolsky DK, Bhan AK. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology. 2002;122(1):134–44.CrossRefPubMed
26.
Otis JS, Niccoli S, Hawdon N, Sarvas JL, Frye MA, Chicco AJ, Lees SJ. Pro-inflammatory mediation of myoblast proliferation. PLoS One. 2014;9(3):e92363.CrossRefPubMedPubMedCentral
27.
Toth KG, McKay BR, De Lisio M, Little JP, Tarnopolsky MA, Parise G. IL-6 induced STAT3 signalling is associated with the proliferation of human muscle satellite cells following acute muscle damage. PLoS One. 2011;6(3):e17392.CrossRefPubMedPubMedCentral
28.
Tierney MT, Aydogdu T, Sala D, Malecova B, Gatto S, Puri PL, Latella L, Sacco A. STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med. 2014;20(10):1182–6.CrossRefPubMedPubMedCentral
29.
Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008;7(1):33–44.CrossRefPubMed
30.
Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, Kempf W, Schubert A, Schuler G, Hambrecht R. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003;42(5):861–8.CrossRefPubMed
31.
Timmerman KL, Dhanani S, Glynn EL, Fry CS, Drummond MJ, Jennings K, Rasmussen BB, Volpi E. A moderate acute increase in physical activity enhances nutritive flow and the muscle protein anabolic response to mixed nutrient intake in older adults. Am J Clin Nutr. 2012;95(6):1403–12.CrossRefPubMedPubMedCentral
32.
Hamilton KE, Simmons JG, Ding S, Van Landeghem L, Lund PK. Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol Cancer Res. 2011;9(12):1718–31.CrossRefPubMedPubMedCentral
33.
Carty SE, Buresh CM, Norton JA. Decreased IL-6 secretion by fibroblasts following repeated doses of TNF alpha or IL-1 alpha: post-transcriptional gene regulation. J Surg Res. 1991;51(1):24–32.CrossRefPubMed
34.
Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, Haykowsky M. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2014;306(9):H1364–70.CrossRefPubMedPubMedCentral
35.
Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies. Circ J. 2013;77(2):293–300.CrossRefPubMed
36.
Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de Lemos JA, Berry JD. Dose-Response Relationship Between Physical Activity and Risk of Heart Failure: A Meta-Analysis. Circulation. 2015;132(19):1786–94.CrossRefPubMed
37.
Rahman I, Bellavia A, Wolk A, Orsini N. Physical Activity and Heart Failure Risk in a Prospective Study of Men. JACC Heart Failure. 2015;3(9):681–7.CrossRefPubMed
38.
Kadi F, Charifi N, Denis C, Lexell J, Andersen JL, Schjerling P, Olsen S, Kjaer M. The behaviour of satellite cells in response to exercise: what have we learned from human studies? Pflugers Arch - Eur J Physiol. 2005;451(2):319–27.CrossRef
39.
Snijders T, Verdijk LB, Beelen M, McKay BR, Parise G, Kadi F, van Loon LJ. A single bout of exercise activates skeletal muscle satellite cells during subsequent overnight recovery. Exp Physiol. 2012;97(6):762–73.CrossRefPubMed
40.
Peake JM, Della Gatta P, Suzuki K, Nieman DC. Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. Exerc Immunol Rev. 2015;21:8–25.PubMed
41.
Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen JL, Christensen LR, Andersen JL. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. J Physiol-London. 2004;558(3):1005–12.CrossRefPubMedPubMedCentral
42.
Crameri RM, Langberg H, Magnusson P, Jensen CH, Schroder HD, Olesen JL, Suetta C, Teisner B, Kjaer M. Changes in satellite cells in human skeletal muscle after a single bout of high intensity exercise. J Physiol-London. 2004;558(1):333–40.CrossRefPubMedPubMedCentral
43.
Begue G, Douillard A, Galbes O, Rossano B, Vernus B, Candau R, Py G. Early activation of rat skeletal muscle IL-6/STAT1/STAT3 dependent gene expression in resistance exercise linked to hypertrophy. PLoS One. 2013;8(2):e57141.CrossRefPubMedPubMedCentral
44.
Will K, Kalbe C, Kuzinski J, Losel D, Viergutz T, Palin MF, Rehfeldt C. Effects of leptin and adiponectin on proliferation and protein metabolism of porcine myoblasts. Histochem Cell Biol. 2012;138(2):271–87.CrossRefPubMed
45.
Baeza-Raja B, Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell. 2004;15(4):2013–26.CrossRefPubMedPubMedCentral
46.
Laustsen PG, Russell SJ, Cui L, Entingh-Pearsall A, Holzenberger M, Liao R, Kahn CR. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol. 2007;27(5):1649–64.CrossRefPubMedPubMedCentral
47.
Machida S, Booth FW. Insulin-like growth factor 1 and muscle growth: implication for satellite cell proliferation. Proc Nutr Soc. 2004;63(2):337–40.CrossRefPubMed
48.
Conejo R, Valverde AM, Benito M, Lorenzo M. Insulin produces myogenesis in C2C12 myoblasts by induction of NF-kappaB and downregulation of AP-1 activities. J Cell Physiol. 2001;186(1):82–94.CrossRefPubMed
49.
Grabiec K, Gajewska M, Milewska M, Blaszczyk M, Grzelkowska-Kowalczyk K. The influence of high glucose and high insulin on mechanisms controlling cell cycle progression and arrest in mouse C2C12 myoblasts: the comparison with IGF-I effect. J Endocrinol Investig. 2014;37(3):233–45.CrossRef
50.
Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard Jr DH, Kull Jr FC, Gonzalez-Cadavid N. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab. 2001;280(2):E221–8.PubMed
51.
Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, Kambadur R. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem. 2000;275(51):40235–43.CrossRefPubMed
52.
McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol. 2003;162(6):1135–47.CrossRefPubMedPubMedCentral
53.
Baba TT, Nemoto TK, Miyazaki T, Oida S. Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. J Muscle Res Cell Motil. 2008;29(2-5):127–34.CrossRefPubMed
54.
Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG, Brandt U, Koopman WJ, Beyrath JD, Rodenburg RJ, et al. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab. 2015;22(3):399–407.CrossRefPubMed
55.
Taha DA, De Moor CH, Barrett DA, Gershkovich P. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res. 2014;164(2):85–109.CrossRefPubMed
56.
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–94.PubMedPubMedCentral
57.
Gaster M, Petersen I, Hojlund K, Poulsen P, Beck-Nielsen H. The diabetic phenotype is conserved in myotubes established from diabetic subjects: evidence for primary defects in glucose transport and glycogen synthase activity. Diabetes. 2002;51(4):921–7.CrossRefPubMed
58.
Zhang L, Wang XH, Wang H, Du J, Mitch WE. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol. 2010;21(3):419–27.CrossRefPubMedPubMedCentral
Metadata
Title
Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity
Authors
Tahnee Sente
An M. Van Berendoncks
An I. Jonckheere
Richard J. Rodenburg
Patrick Lauwers
Viviane Van Hoof
An Wouters
Filip Lardon
Vicky Y. Hoymans
Christiaan J. Vrints
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0278-3

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue

Research article

Where is the exact origin of narrow premature ventricular contractions manifesting qR in inferior wall leads?

Research article

Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome

Research article

Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction

Research article

Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies

Research article

Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study

Research article

Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits